Skip to main content

Advertisement

SpringerLink
Log in

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Direct-acting antivirals (DAAs) for the treatment of HCV have dramatically increased the rate of sustained virological response: patients not achieving sustained virological response represent a challenge and rates of late recurrent viremia are very low. We describe here the first case of a very late HCV relapse, following an atypical kinetics (characterized by a spontaneous but transient HCV clearance after an early virological relapse), in a HIV co-infected patient treated with DAAs. Optimal adherence to the therapy was well documented and a phylogenetic analysis ruled out a possible reinfection from a different HCV strain. In conclusion, our case underlines the importance of a long follow-up (> 48 weeks) after DAAs therapies in HCV–HIV co-infected patients who might benefit the most from a very rigorous virological surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus co-infection in the era of direct-acting antiviral agents: no longer a difficult to treat population. Hepatology. 2017. https://doi.org/10.1002/hep.29642.

    Article  PubMed  Google Scholar 

  2. Kozbial K, Moser S, Al-Zoairy R, et al. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int. 2017. https://doi.org/10.1111/liv.13629.

    Article  PubMed  Google Scholar 

  3. Sarrazin C, Isakov V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 2017;64:44–52.

    Article  PubMed  Google Scholar 

  4. European Association for the Study of the Liver. EASL recommendation on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94.

    Article  Google Scholar 

  5. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677–90.

    Article  CAS  PubMed  Google Scholar 

  6. Conti M, Matulli Cavedagna T, Ramazzotti E, et al. Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS. Clin Mass Spectrom. 2018;7:6–17 (ISSN 2376-9998).

    Article  Google Scholar 

  7. Di Maio VC, Cento V, Lenci I, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514–28.

    Article  CAS  PubMed  Google Scholar 

  8. Uojima H, Murakami S, Nakatani S, et al. Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection with liver cirrhosis. Intern Med. 2017. https://doi.org/10.2169/internalmedicine.9671-17.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Klag T, Dietz J, Wernet CR, et al. Hepatitis C “true” late reslapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. J Hepatol. 2017;66:862–8.

    Article  PubMed  Google Scholar 

  10. Boschi C, Colson P, Tissot-Dupont H, Bernit E, Botta-Fridlund D, Aherfi S. Hepatitis C virus relapse 78 weeks after completion of successful direct-acting therapy. CID. 2017;65:1051–3.

    Article  Google Scholar 

  11. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:683–94.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Neukam K, Morano-Amado LE, Rivero-Juárez A, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017;18:126–34.

    Article  PubMed  Google Scholar 

  13. Sandmann L, Wilson M, Back D, et al. Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. Antiviral Res. 2012;96:51 – 8.

    Article  CAS  PubMed  Google Scholar 

  14. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.03.026

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

    Viola Guardigni, Stefano Ianniruberto, Lorenzo Badia, Pierluigi Viale & Gabriella Verucchi

  2. Research Centre for the Study of Hepatitis, University of Bologna, Bologna, Italy

    Viola Guardigni, Lorenzo Badia & Gabriella Verucchi

  3. University of Milan, Milan, Italy

    Valeria Cento

  4. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

    Marianna Aragri & Francesca Ceccherini-Silberstein

  5. Metropolitan Laboratory, Maggiore Hospital, Bologna, Italy

    Matteo Conti

  6. Department of Oncology and Heamato-Oncology, University of Milan, Milan, Italy

    Carlo Federico Perno

Authors
  1. Viola Guardigni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valeria Cento
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefano Ianniruberto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lorenzo Badia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marianna Aragri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matteo Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carlo Federico Perno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pierluigi Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Francesca Ceccherini-Silberstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gabriella Verucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Viola Guardigni.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standards

The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guardigni, V., Cento, V., Ianniruberto, S. et al. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection 46, 717–720 (2018). https://doi.org/10.1007/s15010-018-1158-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-018-1158-9

Keywords

Search

Navigation